undamentalytics Newsletter
Sign in

Ultragenyx Pharmaceutical Inc. income statement

In fiscal 2025, Ultragenyx Pharmaceutical Inc. reported revenue of $673m, up 20.2% on the year before, operating income of −$535m (a -79.5% margin) and net income of −$575m, or −$5.83 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue0351104271351363434560673717
Cost of revenue—01————————
Gross profit—350————————
Research and development183232294357412497706648698750773
Selling, general and administrative65100128162183220278310321349351
Operating income−248−329−371−424−330−382−649−569−536−535−528
Income before tax−246−318−197−399−185−453−702−609−567−571−582
Income tax0−1613116−2244
Net income−246−302−198−403−187−454−707−607−569−575−586
Diluted EPS−$6.21−$7.12−$3.97−$7.12−$3.07−$6.70−$10.12−$8.25−$6.29−$5.83−$5.83
Diluted shares (average)40m42m50m57m61m68m70m74m91m99m101m
EBITDA−245−323−352−416−318−368−631−543−500−500−495

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: NRIX vs RAREARWR vs RARERARE vs TGTX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Ultragenyx Pharmaceutical Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ultragenyx Pharmaceutical Inc.